PUBBLICAZIONI SCIENTIFICHE


IMPACT FACTOR

L'impact factor dei lavori scientifici è attualmente di 2143.60 punti considerando l'I.F. più recente della rivista


I risultati delle ricerche finanziate dalla Associazione in questi anni sono stati presentati in numerosi convegni e congressi nazionali ed internazionali e pubblicati su importanti riviste scientifiche.

57 – Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

Purpose The aim of the F2 study was to verify whether a prospective collection of data would enable the development of a more accurate

56 – Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: A GISL prospective era

Abstract:  Purpose: In the pre-positron emission tomography era, the Gruppo Italiano Studio Linfomi (GISL) investigated the feasibility and efficacy of a treatment based on

55 – ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial

Purpose To compare doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) versus bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) versus cyclophosphamide, lomustine, vindesine, melphalan, prednisone,

54 – High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results

No abstract available

53 – Identification of Protein Clusters Predictive of Response to Chemotherapy in Breast Cancer Patients

An attempt for the identification of potential biomarkers predictive of response to chemotherapy (CHT) in breast cancer patients has been performed by the use

52 – Second malignancies after treatment of diffuse large B-cell non-Hodgkin’s lymphoma: a GISL cohort study

Background Improved treatment has increased the life expectancy of patients with non-Hodgkin’s lymphoma, but few studies have addressed the issue of second cancer in

51 – The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines

Deregulation of the protein kinase C (PKC) signalling pathway has been implicated in tumor progression. Here we investigated the PKC inhibitor enzastaurin for its

49 – Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy

We conducted a population-based study of peripheral lymphomas (PL) that had been diagnosed between 1997 and 2003 in the province of Modena, Italy, with

46 – Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

BACKGROUND. The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients

45 – Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients

BACKGROUND. It is unclear whether new treatment modalities have improved the survival of follicular lymphoma patients. Some data show that there has been no

44 – Long term results of a randomized study performed by Intergruppo italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuzse large B-cell lymphoma

The Intergruppo Italiano Linfomi started, in 1996, a randomized trial for the initial treatment of elderly patients (older than 65 years) with Diffuse Large

43 – Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients

Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates (BP) at

42 – Cancer incidence in eastern Libya: the first report from the Benghazi Cancer Registry, 2003

Cancer registration in Northern Africa is still limited and, until now, there have been no population-based data available for Libya. In this paper, we

41 – Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations

The presence of genomic rearrangements of the BRCA1 gene in breast and/or ovarian cancer families has been intensively investigated in patients from various countries

40 – Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience

Background: Breast cancer (BC) detection in women with a genetic susceptibility or strong family history is considered mandatory compared with BC screening in the

39 – The prognosis of follicular lymphomas: the F2-project

not available

38 – The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL)

Background: It is still unclear the actual contribute of dose intensity (DI), dose size (DS) and dose density (DD) in the conventional chemotherapy of

37 – Prognosis of follicular lymphomas

Follicular lymphoma (FL) is as an indolent neoplasia with median survival measured in decades. Nevertheless, some patients have poor progression-free survival and overall survival.

36 – The length of treatment of aggressive non-Hodgkin’s lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study

Objectives: To compare two different schedules of two different anthracycline-containing regimens, where length of treatment is modulated according to the international prognostic index (IPI)

35 – The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin’s lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

GISL recently conducted an exhaustive survey of 1078 patients with Hodgkin’s Lymphoma (HL) enrolled between 1988 and 2002 in different prospective trials. Treatment failure

34 – MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin’s Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors

Purpose: MOPPEBVCAD (mechlorethamine, vincristine, procarbazine, prednisone, epidoxirubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine) chemotherapy with limited radiotherapy was devised in 1987 to reduce late

33 – Prognosis of screen-detected breast cancers: results of a population based study

Background: The reduced mortality rate from breast carcinoma among women offered screening mammography is demonstrated after 15–20 years of follow-up. However, the assessment of

32 – ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

Purpose In this multicenter, prospective, randomized clinical trial on advanced Hodgkin’s lymphoma (HL), the efficacy and toxicity of two chemotherapy regimens, doxorubicin, vinblastine, mechlorethamine,

31 – PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract

Aims: To investigate the value of platelet-derived growth factor receptors (PDGFRs) by immunohistochemistry in discriminating KIT-negative gastrointestinal stromal tumours (GISTs) from other soft-tissue neoplasms

30 – A population-based case-control study of diet and melanoma risk in northern Italy

Objective: We aimed at examining the association between dietary constituents and risk of cutaneous melanoma. Design: In an area of northern Italy we recruited

29 – Trace elements and melanoma

Melanoma incidence has been steadily increasing in recent years in most western countries, thus suggesting a role of environmental risk factors. Among these determinants,

28 – Environmental exposure to trace elements and risk of cutaneous melanoma

Purpose: Our aim was to examine the risk of melanoma in association with exposure to trace elements of toxicological and nutritional interest. Methods: We

27 – Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts

The efficacy of All-Trans Retinoic Acid (Atra) and Arsenic Trioxide (As2O3) in the treatment of Acute Promyelocytic Leukemia (APL) is well known. Further, these

26 – FLICE/caspase-8 activation triggers anoikis induced by beta1-integrin blockade in human keratinocytes

β1-integrin protects keratinocyte stem cells (KSC) from cell-detachment apoptosis (‘anoikis’). Here we show that caspase-8 active protein is detected in both young transit amplifying

25 – Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi

BACKGROUND. To assess the impact of T-cell/B-cell phenotype on clinical outcome, the authors retrospectively compared patients who had peripheral T-cell lymphoma, unspecified (PTCL-U), with

24 – Pure red-cell aplasia and epoetin therapy

background Between 1988 and 1998, antibody-associated pure red-cell aplasia was reported in three patients who had undergone treatment with recombinant human erythropoietin (epoetin). Between

23 – The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases

In order to elucidate the role of anthracycline based combination chemotherapy regimens for the treatment of follicular lymphoma we conducted a retrospective study on

22 – Expression and Function of Neurotrophins and Their Receptors in Cultured Human Keratinocytes

Whereas nerve growth factor has been extensively studied in human keratinocytes, little is known on the role of other members of the neurotrophin family.We

21 – High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin’s Lymphoma Responding to Front-Line Therapy

Purpose: To determine whether high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT) should be included in the initial consolidative treatment of patients with advanced,

20 – Mitoxantrone, prednisone, pentostatin and bleomycin for patients with indolent non-Hodgkin’s lymphoma relapsed or unresponsive to previous treatment. Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Backeround. Taking into account the promising results achieved with purine analogs in combination regimens in patients with indolent NHS, we designed a phase II

19 – Prospective study of indolent non-follicular non-Hodgkin’s lymphoma: validation of Gruppo Italiano per lo Studio dei Linfomi (GISL) prognostic criteria for watch and wait policy

Only recently both the Revised European American Lymphoma (REAL) and World Health Organization (WHO) classifications clearly identified indolent non-follicular non-Hodgkin’s lymphoma (NHL) as a

18 – Changes in breast cancer incidence abd stage distribution in Modena, Italy: the effect of a mammographic screening program

Objective: Assessing changes in breast cancer (BC) incidence and stage distribution in the District of Modena, Italy, during the period 1992–1998, and their relationship

17 – Clustering (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression

Clusterin is a highly conserved, widely distributed glycoprotein whose biological significance is still debated. Involved in many biological processes and disease states, clusterin is

16 – Keratinocytes enriched for stem cells are protected from anoikis via an integrin signaling pathway in a Bcl-2 dependent manner

Because inhibition of integrin signaling induces apoptosis, we investigated whether keratinocytes expressing L1 and K6L4 integrins (enriched for stem cells)are protected from cell death.

15 – Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up

Purpose: The purpose of the present study was to assess the risk of second cancers in patients with hairy cell leukemia (HCL). Patients and

14 – Treatment of B-cell non- Hodgkin’s lymphoma with anti CD 20 monoclonal antibody Rituximab

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are

13 – Clinical activity and safety of combination immunotherapy with IFN- a2a and Rituximab in patients with relapsed low grade non-Hodgkin’s lymphoma

Background and Objectives. To determine the clinical activity and safety of the combination immunotherapy of the chimeric anti-CD20 antibody, rituximab, and interferon (IFN)-α2a. Design

12 – BRCA1 mutations and clinicopathological features in a sample of italian women with early-onset breast cancer

Breast cancer in young women is uncommon and often presents with unfavourable biopathological features. Although early age at onset could suggest a genetic susceptibility

11 – Prognosis of follicolar lymphoma: a predictive model based on a retrospective analysis of 987 cases

Patients (n-987) with a histologically confirmed diagnosis of follicular lymphoma were studied with the aim of developing a prognostic model specifically devised for this

10 – Tumor Progression is Accompained by Significant Changes in the Levels of Expression of Polyamine Metabolism Regulatory Genes and Clusterin in Human Prostate Cancer Specimens

Using Northern blotting, the expression levels of the genes for polyamine metabolism regulatory proteins and clusterin have been measured in a series of 23

9 – Bone marrow failure associated with human herpesvirus 8 infection after transplantation

Background Human herpesvirus 8 (HHV-8) infection has been linked to the development of Kaposi’s sarcoma and to rare lymphoproliferative disorders. Methods We used molecular

8 – 2-Deoxy-D-ribose-Induced Apoptosis in HL-60 Cells Is Associated with the Cell Cycle Progression by Spermidine

The presence of polyamines is required for the apoptotic program triggered by 2-deoxy-D-ribose (dRib) in HL-60 cells, but their oxidative metabolites does not appear

RICERCA SUL CANCRO

PUBBLICAZIONI SCIENTIFICHE

Tutti i nostri articoli pubblicati sulle riviste scientifiche
VAI

PROGETTI DI RICERCA

I progetti di ricerca che abbiamo sostenuto
VAI

BORSE DI STUDIO E STAGE ALL'ESTERO

Borse di studio e stage all'estero per ricercatori finanziati dall'Associazione
VAI

PREMI DI STUDIO

Premi di studio per la ricerca contro i tumori
VAI

PREMIO "PIER CAMILLO BECCARIA"

Conferito ogni anno ad un illustre studioso che si è distinto nella lotta contro i tumori
VAI